{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.5","upperLimit":"82.0","value":"64.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"12 cycles","title":"MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}